FDA-Approved Lead Leverage VOWST as a proven microbiome therapy with FDA approval for preventing recurrent C. difficile infections, highlighting commercial potential in partnered distribution through Nestlé Health Science to accelerate market access.

Strategic Partnerships Target health science and pharmaceutical collaborators for co-development and distribution of microbiome therapeutics, emphasizing Seres’ existing collaboration with Nestlé Health Science and opportunities in expanding channel partnerships.

Clinical Expansion Position SER-155 and other pipeline programs (including IBD-focused candidates) for strategic speaking engagements and pilot studies with hospitals and academic centers to generate early revenue through trials or sponsored programs.

Public Funding Highlight non-dilutive funding opportunities (e.g., CARB-X) and government grants to support development of oral liquid SER-155, signaling potential cost offsets and collaborative opportunities with research and health funding entities.

Industry Thought-leadership Leverage participation in industry events (DDW, CARB-X Investor Day, ESCMID conferences) to generate lead generation, present preclinical data, and cultivate relationships with researchers, hospital systems, and potential enterprise customers.